Histone modifying enzymes: novel disease biomarkers and assay development

被引:25
作者
Ma, Fei [1 ]
Zhang, Chun-yang [1 ]
机构
[1] Shandong Normal Univ, Collaborat Innovat Ctr Functionalized Probes Chem, Shandong Prov Key Lab Clean Prod Fine Chem, Coll Chem Chem Engn & Mat Sci,Minist Educ,Key Lab, Jinan, Peoples R China
基金
中国国家自然科学基金;
关键词
Assay development; cancer; disease biomarker; histone modifying enzyme; histone post-transcriptional modification; RUBINSTEIN-TAYBI-SYNDROME; AURORA-B KINASE; DEACETYLASE INHIBITORS; CHROMATIN-STRUCTURE; ANDROGEN-RECEPTOR; TRANSCRIPTIONAL COACTIVATOR; THERAPEUTIC STRATEGY; PROSTATE-CANCER; BREAST-CANCER; GENE;
D O I
10.1586/14737159.2016.1135057
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Histones are the chief components of chromatin. When being catalyzed by a series of histone modifying enzymes, histones may undergo various post-translational modifications such as acetylation, methylation, phosphorylation, ubiquitylation and SUMOylation. The dysregulation of histone modifying enzymes will alter the histone post-modification patterns and cause diverse diseases including cancers. Consequently, the histone modifying enzymes have emerged as the promising biomarkers for disease diagnosis and prognosis. In this review, we summarize the recent researches about the histone modifying enzymes as the disease biomarkers, and highlight the development of methods for histone modifying enzyme assays.
引用
收藏
页码:297 / 306
页数:10
相关论文
共 102 条
[1]   The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma [J].
Aihara, Arihiro ;
Tanaka, Shinji ;
Yasen, Mahmut ;
Matsumura, Satoshi ;
Mitsunori, Yusuke ;
Murakata, Ayano ;
Noguchi, Norio ;
Kudo, Atsushi ;
Nakamura, Noriaki ;
Ito, Koji ;
Arii, Shigeki .
JOURNAL OF HEPATOLOGY, 2010, 52 (01) :63-71
[2]   A rapid and sensitive assay for histone acetyl-transferase activity [J].
Ait-Si-Ali, S ;
Ramirez, S ;
Robin, P ;
Trouche, D ;
Harel-Bellan, A .
NUCLEIC ACIDS RESEARCH, 1998, 26 (16) :3869-3870
[3]   Syndromes of disordered chromatin remodeling [J].
Ausió, J ;
Levin, DB ;
de Amorim, GV ;
Bakker, S ;
Macleod, PM .
CLINICAL GENETICS, 2003, 64 (02) :83-95
[4]   The CBP co-activator is a histone acetyltransferase [J].
Bannister, AJ ;
Kouzarides, T .
NATURE, 1996, 384 (6610) :641-643
[5]   Regulation of chromatin by histone modifications [J].
Bannister, Andrew J. ;
Kouzarides, Tony .
CELL RESEARCH, 2011, 21 (03) :381-395
[6]   PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: A new cancer/testis antigen? [J].
Barrett, A ;
Madsen, B ;
Copier, J ;
Lu, PJ ;
Cooper, L ;
Scibetta, AG ;
Burchell, J ;
Taylor-Papadimitriou, J .
INTERNATIONAL JOURNAL OF CANCER, 2002, 101 (06) :581-588
[7]   High-resolution profiling of histone methylations in the human genome [J].
Barski, Artern ;
Cuddapah, Suresh ;
Cui, Kairong ;
Roh, Tae-Young ;
Schones, Dustin E. ;
Wang, Zhibin ;
Wei, Gang ;
Chepelev, Iouri ;
Zhao, Keji .
CELL, 2007, 129 (04) :823-837
[8]   DNA sequencing of CREBBP demonstrates mutations in 56% of patients with Rubinstein-Taybi syndrome (RSTS) and in another patient with incomplete RSTS [J].
Bartsch, O ;
Schmidt, S ;
Richter, M ;
Morlot, S ;
Seemanová, E ;
Wiebe, G ;
Rasi, S .
HUMAN GENETICS, 2005, 117 (05) :485-493
[9]   MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L [J].
Bernt, Kathrin M. ;
Zhu, Nan ;
Sinha, Amit U. ;
Vempati, Sridhar ;
Faber, Joerg ;
Krivtsov, Andrei V. ;
Feng, Zhaohui ;
Punt, Natalie ;
Daigle, Amanda ;
Bullinger, Lars ;
Pollock, Roy M. ;
Richon, Victoria M. ;
Kung, Andrew L. ;
Armstrong, Scott A. .
CANCER CELL, 2011, 20 (01) :66-78
[10]   Covalent modifications of histones during development and disease pathogenesis [J].
Bhaumik, Sukesh R. ;
Smith, Edwin ;
Shilatifard, Ali .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2007, 14 (11) :1008-1016